

**From America to Europe:
which is the equation that
fulfills the best accuracy?**

**Pierre Delanaye, MD, PhD
University of Liège
CHU Sart Tilman
BELGIUM**





*The State-and-Region Agreement asks for a declaration by Moderators, Speakers, Teachers and Tutors about the frankness of the financing sources and about their relationships with people with commercial interests within the last two years.
The documents must be available at the Provider offices for at least 5 years.*

Conflict of Interests Declaration

Undersigned PIERRE DELANAYE _____ as:

moderator teacher speaker tutor

of the event **“XXX EDIZIONE CORSO CEFAR - LE PROTEINE: DAL LABORATORIO ALLA CLINICA“,
TRIESTE 16 - 18 febbraio 2026”**

Based on Conflict of Interests, of the State-and-Region Agreement in force,
managed by by **SIBioC – Medicina di Laboratorio ETS n. 790**

Declares

that in the last two years DIDN'T have any relationships about comercial financings with people having conflict of interests in the health field

that in the last two years HAD relationships about comercial financings with people having conflict of interests in the health field
(please specify the names):

NEPHROLYX
ALENTIS/MEDPACE
IDS



*The State-and-Region Agreement asks for a declaration by Moderators, Speakers, Teachers and Tutors about the frankness of the financing sources and about their relationships with people with commercial interests within the last two years.
The documents must be available at the Provider offices for at least 5 years.*

SLIDE N.2

Undersigned

First name _____ Pierre _____ Surname _____ DELANAYE _____

Declares, under his responsibility, that in the report entitled

“From America to Europe: which is the equation that fulfils the best accuracy?”

There will be named the following Companies and / or Commercial Products:

_____ None _____


JUST WITH AN EDUCATIONAL AND SCIENTIFIC AIM OR TO REFER TO NATIONAL OR INTERNATIONAL GUIDELINES

The Glomerular Filtration Rate is usually the best parameter to assess the global kidney function.



Homer William Smith (January 2, 1895 – March 25, 1962)

- GFR is estimated with biomarkers
- Serum creatinine is one the most prescribed analysis
- The most important is probably to know the limitations...



NephroTest Cohort (France)
 Which GFR for patients with
 serum creatinine measured
 at $80 \mu\text{mol/L}$ (0.9 mg/dL)?

IC 95% for subjects <65 years old
 IC 95% for subjects >65 years old

S. Creatinine lab
 normality range

Other Limitations

Analytical

- Jaffe methods
- Enzymatic methods
- Jaffe and enzymatic methods gives slightly different results
- Pseudochromogen: glucose, fructose, ascorbate, proteins, urate, acetoacetate, acetone, pyruvate => false positive
- Bilirubins: false negative

Physiological: Tubular secretion

- 10 to 40%
- Increase with decreased GFR
- Unpredictable at the individual level !

Physiological: Muscular mass

- Production (relatively) constant but muscular production => serum creatinine is dependent of muscular mass, not only GFR (age? sex/gender? race/population?)
- Extra-renal production

Perrone RD, Clin Chem, 1992, 38, p1933

Delanaye P, Nephron, 2017, 136, p302

Creatinine: to the trash?

- Very cheap (0.04€ /Jaffe)
- Good specificity
- Good analytical CV, IDMS traceability

Creatinine clearance

- Not recommended
- Creatinine tubular secretion
- Lack of precision:

errors in urine collection


22 to 27% for « trained » patients

50 to 70 % for others

large intra-individual variability for
creatinine excretion

Statistics

- Good correlation: a “*sine qua non*” condition but insufficient
- Bias: mean difference between two values = the systematic error
- Precision: SD around the bias = the random error
- Accuracy 30% = % of eGFR between $\pm 30\%$ of measured GFR



Which one?

- Cockcroft
- CKD-EPI
- EKFC

Which one?

- ~~• Cockcroft~~
- CKD-EPI
- EKFC

The CKD-EPI equation

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, MD; Lesley A. Stevens, MD, MS; Christopher H. Schmid, PhD; Yaping (Lucy) Zhang, MS; Alejandro F. Castro III, MPH; Harold I. Feldman, MD, MSCE; John W. Kusek, PhD; Paul Eggers, PhD; Frederick Van Lente, PhD; Tom Greene, PhD; and Josef Coresh, MD, PhD, MHS, for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)*


Ann Intern Med. 2009;150:604-612.

Table 2. The CKD-EPI Equation for Estimating GFR on the Natural Scale*

Race and Sex	Serum Creatinine Level, $\mu\text{mol/L}$ (mg/dL)	Equation
Black		
Female	≤ 62 (≤ 0.7)	$\text{GFR} = 166 \times (\text{Scr}/0.7)^{-0.329} \times (0.993)^{\text{Age}}$
	> 62 (> 0.7)	$\text{GFR} = 166 \times (\text{Scr}/0.7)^{-1.209} \times (0.993)^{\text{Age}}$
Male	≤ 80 (≤ 0.9)	$\text{GFR} = 163 \times (\text{Scr}/0.9)^{-0.411} \times (0.993)^{\text{Age}}$
	> 80 (> 0.9)	$\text{GFR} = 163 \times (\text{Scr}/0.9)^{-1.209} \times (0.993)^{\text{Age}}$
White or other		
Female	≤ 62 (≤ 0.7)	$\text{GFR} = 144 \times (\text{Scr}/0.7)^{-0.329} \times (0.993)^{\text{Age}}$
	> 62 (> 0.7)	$\text{GFR} = 144 \times (\text{Scr}/0.7)^{-1.209} \times (0.993)^{\text{Age}}$
Male	≤ 80 (≤ 0.9)	$\text{GFR} = 141 \times (\text{Scr}/0.9)^{-0.411} \times (0.993)^{\text{Age}}$
	> 80 (> 0.9)	$\text{GFR} = 141 \times (\text{Scr}/0.9)^{-1.209} \times (0.993)^{\text{Age}}$

- CKD-EPI
- Development dataset: n=5504
- Internal validation: n=2750
- External validation: n=3896
- Creatinine calibrated
- Median GFR in the development = 68 mL/min/1.73 m²

Figure. Performance of the CKD-EPI and MDRD Study equations in estimating measured GFR in the external validation data set.



KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

VOLUME 3 | ISSUE 1 | JANUARY 2013

<http://www.kidney-international.org>



CKD-EPI: What else?

Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate

A Cross-sectional Analysis of Pooled Data

Hans Pottel, PhD*; Jonas Björk, PhD*; Marie Courbebaisse, MD, PhD; Lionel Couzi, MD, PhD; Natalie Ebert, MD, MPH; Björn O. Eriksen, MD, PhD; R. Neil Dalton, PhD; Laurence Dubourg, MD, PhD; François Gaillard, MD, PhD; Cyril Garrouste, MD; Anders Grubb, MD, PhD; Lola Jacquemont, MD, PhD; Magnus Hansson, MD, PhD; Nassim Kamar, MD, PhD; Edmund J. Lamb, PhD; Christophe Legendre, MD; Karin Littmann, MD; Christophe Mariat, MD, PhD; Toralf Melsom, MD, PhD; Lionel Rostaing, MD, PhD; Andrew D. Rule, MD; Elke Schaeffner, MD, PhD, MSc; Per-Ola Sundin, MD, PhD; Stephen Turner, MD, PhD; Arend Bökenkamp, MD; Ulla Berg, MD, PhD; Kajsa Åsling-Monemi, MD, PhD; Luciano Selistre, MD, PhD; Anna Åkesson, BSc; Anders Larsson, MD, PhD; Ulf Nyman, MD, PhD†; and Pierre Delanaye, MD, PhD†

- Participants with measured GFR and IDMS traceable creatinine
- 13 cohorts
- N=11,251 for development and internal validation
- N=8,378 for external validation
- Mostly White Europeans

1-18 years

- Development: n=2056
- Internal validation: n=695
- External Validation: n=1254

TOTAL: 4,005

Figure 1. The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (SCr/Q)^{-0.322}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132}$
>40 y	<1	$107.3 \times (SCr/Q)^{-0.322} \times 0.990^{(Age - 40)}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132} \times 0.990^{(Age - 40)}$

Q Values

For ages 2–25 y:

Males:

$$\ln(Q) = 3.200 + 0.259 \times Age - 0.543 \times \ln(Age) - 0.00763 \times Age^2 + 0.0000790 \times Age^3$$

Females:

$$\ln(Q) = 3.080 + 0.177 \times Age - 0.223 \times \ln(Age) - 0.00596 \times Age^2 + 0.0000686 \times Age^3$$

For ages >25 y:

Males:

$$Q = 80 \mu\text{mol/L (0.90 mg/dL)}$$

Females:

$$Q = 62 \mu\text{mol/L (0.70 mg/dL)}$$

SCr and Q in $\mu\text{mol/L}$ (to convert to mg/dL, divide by 88.4)

Q values (in $\mu\text{mol/L}$ or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.

Figure 1. The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (\text{SCr}/\text{Q})^{-1.322}$
	≥ 1	$107.3 \times (\text{SCr}/\text{Q})^{-1.132}$
>40 y	<1	$107.3 \times (\text{SCr}/\text{Q})^{-1.322} \times 0.990^{(\text{Age} - 40)}$
	≥ 1	$107.3 \times (\text{SCr}/\text{Q})^{-1.132} \times 0.990^{(\text{Age} - 40)}$

Q Values

For ages 2–25 y:

Males:

$$\ln(\text{Q}) = 3.200 + 0.259 \times \text{Age} - 0.543 \times \ln(\text{Age}) - 0.00763 \times \text{Age}^2 + 0.0000790 \times \text{Age}^3$$

Females:

$$\ln(\text{Q}) = 3.080 + 0.177 \times \text{Age} - 0.223 \times \ln(\text{Age}) - 0.00596 \times \text{Age}^2 + 0.0000686 \times \text{Age}^3$$

For ages >25 y:

Males:

$$\text{Q} = 80 \mu\text{mol/L} (0.90 \text{ mg/dL})$$

Females:

$$\text{Q} = 62 \mu\text{mol/L} (0.70 \text{ mg/dL})$$

SCr and Q in $\mu\text{mol/L}$ (to convert to mg/dL, divide by 88.4)

Q values (in $\mu\text{mol/L}$ or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.

Figure 1. The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (SCr/Q)^{-0.322}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132}$
>40 y	<1	$107.3 \times (SCr/Q)^{-0.322} \times 0.990^{(Age - 40)}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132} \times 0.990^{(Age - 40)}$

Q Values

For ages 2–25 y:

Males:

$$\ln(Q) = 3.200 + 0.259 \times Age - 0.543 \times \ln(Age) - 0.00763 \times Age^2 + 0.0000790 \times Age^3$$

Females:

$$\ln(Q) = 3.080 + 0.177 \times Age - 0.223 \times \ln(Age) - 0.00596 \times Age^2 + 0.0000686 \times Age^3$$

For ages >25 y:

Males:

$$Q = 80 \mu\text{mol/L (0.90 mg/dL)}$$

Females:

$$Q = 62 \mu\text{mol/L (0.70 mg/dL)}$$

SCr and Q in $\mu\text{mol/L}$ (to convert to mg/dL, divide by 88.4)

Q values (in $\mu\text{mol/L}$ or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.

Pierre Delanaye*, François Gaillard, Jessica van der Weijden, Geir Mjøen, Ingela Ferhman-Ekholm, Laurence Dubourg, Natalie Ebert, Elke Schaeffner, Torbjörn Åkerfeldt, Karolien Goffin, Lionel Couzi, Cyril Garrouste, Lionel Rostaing, Marie Courbebaisse, Christophe Legendre, Maryvonne Hourmant, Nassim Kamar, Etienne Cavalier, Laurent Weekers, Antoine Bouqueneau, Martin H. de Borst, Christophe Mariat, Hans Pottel and Marco van Londen

Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65 years

Before 40 y: mGFR = 107 mL/min/1.73m²
...and it seems universal...




Figure 3: mGFR according to age in the development (dark dots) and external validation cohort (n=329) (gray dots). Red lines are percentiles 5, 10, 50, 90 and 95, calculated from kidney donors younger than 65 years and extrapolated for ages >65 years.

Pierre Delanaye*, François Gaillard, Jessica van der Weijden, Geir Mjøen, Ingela Ferhman-Ekholm, Laurence Dubourg, Natalie Ebert, Elke Schaeffner, Torbjörn Åkerfeldt, Karolien Goffin, Lionel Couzi, Cyril Garrouste, Lionel Rostaing, Marie Courbebaisse, Christophe Legendre, Maryvonne Hourmant, Nassim Kamar, Etienne Cavalier, Laurent Weekers, Antoine Bouquegneau, Martin H. de Borst, Christophe Mariat, Hans Pottel and Marco van Londen

Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65 years

Before 40 y: mGFR = 107 mL/min/1.73m²
...and it seems universal...






Figure 3: mGFR according to age in the development (dark dots) and external validation cohort (n=329) (gray dots). Red lines are percentiles 5, 10, 50, 90 and 95, calculated from kidney donors younger than 65 years and extrapolated for ages >65 years.



N=83,257 from three labs
(Sweden, Belgium)

62 $\mu\text{mol/L}$ = 0,70 mg/dL



80 $\mu\text{mol/L}$ = 0,90 mg/dL

Figure 1. The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (SCr/Q)^{-0.322}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132}$
>40 y	<1	$107.3 \times (SCr/Q)^{-0.322} \times 0.990^{(Age - 40)}$
	≥ 1	$107.3 \times (SCr/Q)^{-1.132} \times 0.990^{(Age - 40)}$

Q Values

For ages 2–25 y:

Males:

$$\ln(Q) = 3.200 + 0.259 \times Age - 0.543 \times \ln(Age) - 0.00763 \times Age^2 + 0.0000790 \times Age^3$$

Females:

$$\ln(Q) = 3.080 + 0.177 \times Age - 0.223 \times \ln(Age) - 0.00596 \times Age^2 + 0.0000686 \times Age^3$$

For ages >25 y:

Males:

$$Q = 80 \mu\text{mol/L (0.90 mg/dL)}$$

Females:

$$Q = 62 \mu\text{mol/L (0.70 mg/dL)}$$

SCr and Q in $\mu\text{mol/L}$ (to convert to mg/dL, divide by 88.4)

Q values (in $\mu\text{mol/L}$ or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.

Figure 1. The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (\text{SCr}/Q)^{-0.322}$
	≥ 1	$107.3 \times (\text{SCr}/Q)^{-1.132}$
>40 y	<1	$107.3 \times (\text{SCr}/Q)^{-0.322} \times 0.990^{(\text{Age} - 40)}$
	≥ 1	$107.3 \times (\text{SCr}/Q)^{-1.132} \times 0.990^{(\text{Age} - 40)}$

Q Values

For ages 2–25 y:

Males:

$$\ln(Q) = 3.200 + 0.259 \times \text{Age} - 0.543 \times \ln(\text{Age}) - 0.00763 \times \text{Age}^2 + 0.0000790 \times \text{Age}^3$$

Females:

$$\ln(Q) = 3.080 + 0.177 \times \text{Age} - 0.223 \times \ln(\text{Age}) - 0.00596 \times \text{Age}^2 + 0.0000686 \times \text{Age}^3$$

For ages >25 y:

Males:


$$Q = 80 \mu\text{mol/L} (0.90 \text{ mg/dL})$$


Females:

$$Q = 62 \mu\text{mol/L} (0.70 \text{ mg/dL})$$

SCr and Q in $\mu\text{mol/L}$ (to convert to mg/dL, divide by 88.4)

Q values (in $\mu\text{mol/L}$ or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.








Figure S8. P30-accuracy against age for the EKFC, FAS, CKiD and CKD-EPI equation in the external validation dataset. P30 (%) was graphically presented across the age spectrum using cubic splines with two free knots and using 3rd degree polynomials.

EKFC: added value

- Better performance (not more expensive)
- More « physiological»: correction at the serum creatinine level (sex, race), age better conceptualized, « Q » specific to specific populations
- Valid from 2y to old ages
- Children: no need for height
- No implausible jump at transition adolescence/young adults

Debate on the race factor in USA

Serum creatinine is different between Black and non-Black people in USA (and we don't know why!)

(normal) mGFR is not different

The race coefficient in the CKD-EPI₂₀₀₉ was considered as a source of discrimination



ORIGINAL ARTICLE

New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race

L.A. Inker, N.D. Eneanya, J. Coresh, H. Tighiouart, D. Wang, Y. Sang, D.C. Crews, A. Doria, M.M. Estrella, M. Froissart, M.E. Grams, T. Greene, A. Grubb, V. Gudnason, O.M. Gutiérrez, R. Kalil, A.B. Karger, M. Mauer, G. Navis, R.G. Nelson, E.D. Poggio, R. Rodby, P. Rossing, A.D. Rule, E. Selvin, J.C. Seegmiller, M.G. Shlipak, V.E. Torres, W. Yang, S.H. Ballew, S.J. Couture, N.R. Powe, and A.S. Levey, for the Chronic Kidney Disease Epidemiology Collaboration*

➤ [N Engl J Med. 2021 Nov 4;385\(19\):1737-1749.](#)

Table 3. Accuracy of Current and New Approaches for GFR Estimation as Compared with Measured GFR in the Validation Data Set.

Filtration Marker and Equation*	Black Participants	Non-Black Participants	Difference between Black Participants and Non-Black Participants (95% CI)†
Bias: Median Difference between Measured GFR and eGFR (95% CI)‡			
<i>milliliters per minute per 1.73 square meters</i>			
Creatinine			
eGFRcr(ASR), current	-3.7 (-5.4 to -1.8)	-0.5 (-0.9 to 0.0)	-3.2 (-5.0 to -1.3)
eGFRcr(ASR-NB), new	7.1 (5.9 to 8.8)	-0.5 (-0.9 to 0.0)	7.6 (6.1 to 9.0)
eGFRcr(AS), new	3.6 (1.8 to 5.5)	-3.9 (-4.4 to -3.4)	7.6 (5.6 to 9.5)
Creatinine			
eGFRcr(ASR), current	85.1 (82.2 to 87.9)	89.5 (88.5 to 90.4)	-4.4 (-7.6 to -1.2)
eGFRcr(ASR-NB), new	86.4 (83.4 to 89.1)	89.5 (88.5 to 90.4)	-3.1 (-6.2 to 0)
eGFRcr(AS), new	87.2 (84.5 to 90.0)	86.5 (85.4 to 87.6)	0.7 (-2.4 to 3.8)

NKF and ASN Release New Way to Diagnose Kidney Diseases



Both Organizations Recommend Race-Free Approach to Estimate GFR

Sept. 23, 2021, New York, NY - Today, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases has released its final report, which outlines a new race-free approach to diagnose kidney disease. In the report, the NKF-ASN Task Force recommends the adoption of the **new eGFR 2021 CKD EPI creatinine** equation that estimates kidney function without a race variable. The task force also recommended increased use of **cystatin C** combined with serum (blood) creatinine, as a confirmatory assessment of GFR or kidney function.

Ethnic/race factor in Europe/Africa?

RESEARCH LETTER

Performance of GFR Estimating Equations in African Europeans: Basis for a Lower Race-Ethnicity Factor Than in African Americans

Flamant M et al Am J Kidney Dis, 2013, 62, p179

NO !

Hindawi
International Journal of Nephrology
Volume 2020, Article ID 2141035, 9 pages
<https://doi.org/10.1155/2020/2141035>



Research Article

No Race-Ethnicity Adjustment in CKD-EPI Equations Is Required for Estimating Glomerular Filtration Rate in the Brazilian Population

ARTICLE IN PRESS

www.kidney-international.org

clinicalinvestigation

Performance of creatinine- or cystatin C-based equations to estimate glomerular filtration rate in sub-Saharan African populations

Justine B. Bukabau^{1,7}, Eric Yayo^{2,7}, Appolinaire Gnionsahé³, Dagui Monnet², Hans Pottel⁴, Etienne Cavalier⁵, Aliocha Nkodila¹, Jean Robert R. Makulo¹, Vieux M. Mokoli¹, François B. Lepira¹, Nazaire M. Nseka¹, Jean-Marie Krzesinski⁶, Ernest K. Sumaili^{1,7} and Pierre Delanaye^{6,7}

¹Renal Unit, Department of Internal Medicine, Kinshasa University Hospital, University of Kinshasa, Kinshasa, Democratic Republic of Congo; ²Département de Biochimie, UFR Sciences Pharmaceutiques et Biologiques, Université Felix Houphouët Boigny, Abidjan, Ivory Coast; ³Département de Néphrologie, UFR Sciences Médicales, Université Felix Houphouët Boigny, Abidjan, Ivory Coast; ⁴Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium; ⁵Division of Clinical Chemistry, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium; and ⁶Division of Nephrology-Dialysis-Transplantation, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium

Yayo ES, Nephrol Ther, 2016, 12, p454
Flamant M, Am J Kidney Dis, 2013, 62, p179
Bukabau JB, Plos One, 2018, 13, e0193384
Bukabau JB, Kidney Int, 2019, 95, p1181




RESEARCH ARTICLE

Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction

Justine B. Bukabau^{1*}, Ernest K. Sumaili¹, Etienne Cavalier², Hans Pottel³, Bejos Kifakiou⁴, Aliocha Nkodila¹, Jean Robert R. Makulo¹, Vieux M. Mokoli¹, Chantal V. Zinga¹, Augustin L. Longo¹, Yannick M. Engole¹, Yannick M. Nlandu¹, François B. Lepira¹, Nazaire M. Nseka¹, Jean Marie Krzesinski⁴, Pierre Delanaye⁴

¹ Renal Unit, Department of Internal medicine, Kinshasa University Hospital, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, ² Division of Clinical Chemistry, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium, ³ Division of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium, ⁴ Division of Nephrology-Dialysis-Transplantation, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium

* justinebuk@yahoo.fr



Americentrism in estimation of glomerular filtration rate equations



Pierre Delanaye^{1,2},
Hans Pottel³ and
Richard J. Glassock⁴

¹Department of Nephrology-Dialysis-Transplantation, University of Liège, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium; ²Department of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carêmeau, Nîmes, France; ³Department of Public Health and Primary Care, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Kortrijk, Belgium; and ⁴Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, California, USA

Correspondence: Pierre Delanaye, Service de Dialyse, Centre Hospitalier Universitaire Sart Tilman, 4000 Liège, Belgium. E-mail: pierre_delanaye@yahoo.fr

Kidney International (2022) **101**, 856–858; <https://doi.org/10.1016/j.kint.2022.02.022>

KEYWORDS: glomerular filtration rate; race; serum creatinine

Copyright © 2022, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

THE WORLD ACCORDING TO AMERICANS





Equality

Race-free



Equity

Population-specific












Nephrology Dialysis Transplantation (2023) 38: 106–118

<https://doi.org/10.1093/ndt/gfac241>

Advance Access publication date 24 August 2022




Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa

Pierre Delanaye ^{1,2,*}, Emmanuelle Vidal-Petiot ^{3,*}, Jonas Björk ^{4,5}, Natalie Ebert ⁶, Björn O. Eriksen⁷, Laurence Dubourg⁸, Anders Grubb⁹, Magnus Hansson¹⁰, Karin Littmann¹¹, Christophe Mariat¹², Toralf Melsom⁷, Elke Schaeffner⁶, Per-Ola Sundin ¹³, Arend Bökenkamp¹⁴, Ulla B. Berg¹⁵, Kajsa Åsling-Monemi¹⁵, Anna Åkesson^{4,5}, Anders Larsson¹⁶, Etienne Cavalier ¹⁷, R. Neil Dalton¹⁸, Marie Courbebaisse¹⁹, Lionel Couzi ²⁰, Francois Gaillard ²¹, Cyril Garrouste²², Lola Jacquemont²³, Nassim Kamar²⁴, Christophe Legendre²⁵, Lionel Rostaing ²⁶, Thomas Stehlé ^{27,28}, Jean-Philippe Haymann²⁹, Luciano da Silva Selistre³⁰, Jorge P. Strogoff-de-Matos ³¹, Justine B. Bukabau³², Ernest K. Sumaili³², Eric Yayo³³, Dagui Monnet³³, Ulf Nyman³⁴, Hans Pottel^{35,†} and Martin Flamant^{36,†}


Methods

- Adults, measured GFR, IDMS creatinine
- EKFC consortium: 11 cohorts from Europe (n=17,321)
- Data from Paris (n=4,429, among them 964 Black Europeans)
- Data from Africa (RDC and Côte d'Ivoire, n=508)


White Europeans (n=17,321)



Black Europeans (n=964)



Black Africans (n=508)



EFLM Paper

Pierre Delanaye, Elke Schaeffner, Mario Cozzolino, Michel Langlois, Mario Plebani, Tomris Ozben and Etienne Cavalier*, on behalf of the Board members of the EFLM Task Group Chronic Kidney Diseases

The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)


Nephrol Dial Transplant (2023) 38: 1–6

<https://doi.org/10.1093/ndt/gfac254>

Advance Access publication date 7 September 2022



What should European nephrology do with the new CKD-EPI equation?

Ron T. Gansevoort ¹, Hans-Joachim Anders², Mario Cozzolino³, Danilo Fliser⁴, Denis Fouque⁵, Alberto Ortiz^{6,7}, Maria José Soler⁸ and Christoph Wanner⁹

¹Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, ²Renal Division, Hospital of the Ludwig Maximilians University, Munich, Germany, ³Department of Health Sciences, University of Milan, Renal Division, ASST Santi Paolo e Carlo, Milan, Italy, ⁴Department of Internal Medicine IV, Renal and Hypertensive Disease, University Medical Center, Homburg, Saar, Germany, ⁵Department of Nephrology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Benite, University of Lyon, France, ⁶Department of Nephrology, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ⁷Department of Medicine, Universidad Autonoma de Madrid, Madrid, Spain, ⁸Department of Nephrology, Hospital Vall d'Hebron, Barcelona, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain and ⁹Department of Internal Medicine I and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany

Correspondence to: Ron T. Gansevoort; E-mail: r.t.gansevoort@umcg.nl

Performance of the European Kidney Function Consortium (EKFC) creatinine-based equation in United States cohorts



see commentary on page 445

Pierre Delanaye^{1,2,16}, Andrew D. Rule^{3,16}, Elke Schaeffner^{4,16}, Etienne Cavalier^{5,16}, Junyan Shi^{6,7}, Andrew N. Hoofnagle^{7,8,9,10}, Ulf Nyman^{11,16}, Jonas Björk^{12,13,15,16} and Hans Pottel^{14,15,16}

¹Department of Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium; ²Department of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carémeau, Nîmes, France; ³Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; ⁴Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin, Germany; ⁵Department of Clinical Chemistry, University of Liège, CHU Sart Tilman, Liège, Belgium; ⁶Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; ⁷Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA; ⁸Kidney Research Institute, Department of Medicine, University of Washington, Seattle, Washington, USA; ⁹Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington, USA; ¹⁰Department of Medicine, University of Washington, Seattle, Washington, USA; ¹¹Department of Translational Medicine, Division of Medical Radiology, Lund University, Malmö, Sweden; ¹²Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden; ¹³Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden; and ¹⁴Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

Kidney International (2024) **105**, 629–637;

Validation of EKFC in US populations

Cohorts	Sample Size	Age (years)	Measured GFR (mL/min/1.73m²)	% of women	% of Black subjects	Proportion of individuals with urinary clearance data available
<i>All</i>	12,854	56.0 [22.1]	57 [46]	44.3	21.7	93.2
AASK	1,844	54.5 [16.0]	57 [35]	35.9	100	100
ALTOLD	381	43.3 [19.0]	97 [18]	65.1	1.8	0
CRIC	1,194	59.0 [17.7]	48 [28]	44.4	44.7	100
CRISP	217	34.0 [13.0]	93 [34]	59.0	11.1	100
DCCT/EDIC	809	31.0 [9.0]	119 [25]	47.8	1.4	100
GENOA/ECAC	1,093	66.1 [12.1]	80 [27]	56.6	0	100
Mayo Clinic	5,069	59.0 [21.0]	50 [40]	44.6	2.0	100
MDRD	1,756	51.0 [21.0]	36 [29]	39.5	12.4	100
PERL	491	52.0 [15.0]	70 [25]	33.6	10.8	0

Results are expressed in % or Median [interquartile range].

GFR: glomerular filtration rate


Q-values could be population specific

Q-values determined in different populations


	Q value in women	Q value in men	Origine
White European	0.70	0.90	Large data from laboratories in Sweden and Belgium
Black European	0.74	1.02	Living kidney donors in Paris
Black Africans (Central Africa)	0.72	0.96	Healthy people in Congo
White US population-specific	0.73	0.93	Large data from laboratories from University of Washington Medicine System
Black US population-specific	0.73	1.00	Large data from laboratories from University of Washington Medicine System
White US population-specific	0.70	0.94	National Health and Nutrition Examination Survey
Black US population-specific	0.72	1.03	National Health and Nutrition Examination Survey
US race-free	0.73	0.97	Large data from laboratories from University of Washington Medicine System
China	0.62	0.88	27,830 healthy people

All results are expressed in mg/dL

A



B



Glomerular Filtration Rate Estimation in Adults: Myths and Promises

Pierre Delanaye^{a,b} Etienne Cavalier^c Thomas Stehlé^d Hans Pottel^e

^aDepartment of Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium;

^bDepartment of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carémeau, Nîmes, France; ^cDepartment of Clinical Chemistry, University of Liège, CHU Sart Tilman, Liège, Belgium; ^dAssistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Fédération Hospitalo-Universitaire "Innovative Therapy for Immune Disorders", Créteil, France; ^eDepartment of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

- The main advantage of EKFC is its flexibility
- Q can be adapted to every population
- Including a mixed “racial” population
- Q can be obtained from large or very specific databases
- Q can be obtained in every hospital (true “local” Q)

Cystatin C

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C

Lesley A. Inker, M.D., Christopher H. Schmid, Ph.D., Hocine Tighiouart, M.S.,
John H. Eckfeldt, M.D., Ph.D., Harold I. Feldman, M.D., Tom Greene, Ph.D.,
John W. Kusek, Ph.D., Jane Manzi, Ph.D., Frederick Van Lente, Ph.D.,
Yaping Lucy Zhang, M.S., Josef Coresh, M.D., Ph.D., and Andrew S. Levey, M.D.,
for the CKD-EPI Investigators*

Table 1. Characteristics of Study Participants, According to Data Set.*

Characteristic	Development and Internal Validation (N = 5352)	External Validation (N = 1119)	P Value
Age — yr	47±15	50±17	<0.001
Age group — no. (%)			
<40 yr	2008 (38)	357 (32)	<0.001
40–65 yr	2625 (49)	530 (47)	
>65 yr	719 (13)	232 (21)	
Male sex — no. (%)	3107 (58)	663 (59)	0.46
Black race — no. (%)†	2123 (40)	30 (3)	<0.001
Diabetes — no. (%)	1726 (32)	594 (53)	<0.001
Body-mass index‡			
Mean	28±6	25±4	<0.001
<20 — no. (%)	214 (4)	81 (7)	<0.001
20–24 — no. (%)	1585 (30)	503 (45)	
25–30 — no. (%)	1881 (35)	386 (35)	
>30 — no. (%)	1671 (31)	149 (13)	
Mean weight — kg	83±20	74±15	<0.001
Mean height — cm	171±10	170±9	0.017
Mean body-surface area — m ²	1.94±0.24	1.85±0.21	<0.001
Mean serum cystatin C — ml/liter	1.4±0.7	1.5±0.8	0.01
Mean serum creatinine — mg/dl§	1.6±0.9	1.6±1.1	0.15
Mean measured GFR — ml/min/1.73 m ² of body-surface area	68±39	70±41	0.13
Measured GFR — no. (%)			
<15 ml/min/1.73 m ²	160 (3)	51 (5)	<0.001
15–29 ml/min/1.73 m ²	785 (15)	166 (15)	
30–59 ml/min/1.73 m ²	1765 (33)	316 (28)	
60–89 ml/min/1.73 m ²	1105 (21)	215 (19)	
90–119 ml/min/1.73 m ²	862 (16)	199 (18)	
>120 ml/min/1.73 m ²	675 (13)	172 (15)	

Table 2. Creatinine Equation (CKD-EPI 2009), Cystatin C Equation (CKD-EPI 2012), and Creatinine–Cystatin C Equation (CKD-EPI 2012) for Estimating GFR, Expressed for Specified Sex, Serum Creatinine Level, and Serum Cystatin C Level.*

Basis of Equation and Sex	Serum Creatinine†	Serum Cystatin C	Equation for Estimating GFR
	mg/dl	mg/liter	
CKD-EPI creatinine equation‡			
Female	≤0.7		$144 \times (\text{Scr}/0.7)^{-0.329} \times 0.993^{\text{Age}} [\times 1.159 \text{ if black}]$
Female	>0.7		$144 \times (\text{Scr}/0.7)^{-1.209} \times 0.993^{\text{Age}} [\times 1.159 \text{ if black}]$
Male	≤0.9		$141 \times (\text{Scr}/0.9)^{-0.411} \times 0.993^{\text{Age}} [\times 1.159 \text{ if black}]$
Male	>0.9		$141 \times (\text{Scr}/0.9)^{-1.209} \times 0.993^{\text{Age}} [\times 1.159 \text{ if black}]$
CKD-EPI cystatin C equation§			
Female or male		≤0.8	$133 \times (\text{Scys}/0.8)^{-0.499} \times 0.996^{\text{Age}} [\times 0.932 \text{ if female}]$
Female or male		>0.8	$133 \times (\text{Scys}/0.8)^{-1.328} \times 0.996^{\text{Age}} [\times 0.932 \text{ if female}]$
CKD-EPI creatinine–cystatin C equation¶			
Female	≤0.7	≤0.8	$130 \times (\text{Scr}/0.7)^{-0.248} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
		>0.8	$130 \times (\text{Scr}/0.7)^{-0.248} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
Female	>0.7	≤0.8	$130 \times (\text{Scr}/0.7)^{-0.601} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
		>0.8	$130 \times (\text{Scr}/0.7)^{-0.601} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
Male	≤0.9	≤0.8	$135 \times (\text{Scr}/0.9)^{-0.207} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
		>0.8	$135 \times (\text{Scr}/0.9)^{-0.207} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
Male	>0.9	≤0.8	$135 \times (\text{Scr}/0.9)^{-0.601} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$
		>0.8	$135 \times (\text{Scr}/0.9)^{-0.601} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{Age}} [\times 1.08 \text{ if black}]$

Table 3. Use of the CKD-EPI Creatinine Equation (2009), CKD-EPI Cystatin C Equation (2012), and CKD-EPI Creatinine–Cystatin C Equations (2012) in the External-Validation Data Set Comprising 1119 Participants.*

Variable	Estimated GFR			
	Overall	<60	60–89	≥90
	<i>ml/min/1.73 m² of body-surface area</i>			
Bias — median difference (95% CI)				
Creatinine equation	3.7 (2.8 to 4.6)	1.8 (1.1 to 2.5)	6.6 (3.5 to 9.2)	11.1 (8.0 to 12.5)
Cystatin C equation	3.4 (2.3 to 4.4)	0.4 (–0.5 to 1.4)	6.0 (4.6 to 8.5)	8.5 (6.5 to 11.2)
Creatinine–cystatin C equation	3.9 (3.2 to 4.5)	1.3 (0.5 to 1.8)	6.9 (5.0 to 8.9)	10.6 (9.5 to 12.7)
Average of creatinine and cystatin C†	3.5 (2.8 to 4.1)	0.4 (–0.3 to 0.8)	6.5 (4.6 to 8.4)	11.9 (9.9 to 13.9)
Precision — IQR of the difference (95% CI)				
Creatinine equation	15.4 (14.3 to 16.5)	10.0 (8.9 to 11.0)	19.6 (17.3 to 23.2)	25.0 (21.6 to 28.1)
Cystatin C equation	16.4 (14.8 to 17.8)	11.0 (10.0 to 12.4)	19.6 (16.1 to 23.1)	22.6 (18.8 to 26.3)
Creatinine–cystatin C equation	13.4 (12.3 to 14.5)	8.1 (7.3 to 9.1)	15.9 (13.9 to 18.1)	18.8 (16.8 to 22.5)
Average of creatinine and cystatin C equations†	13.9 (12.9 to 14.7)	7.9 (7.1 to 9.0)	15.8 (13.9 to 17.7)	18.6 (16.1 to 22.2)
Accuracy — % (95% CI)‡				
1–P ₃₀				
Creatinine equation	12.8 (10.9 to 14.7)	16.6 (13.6 to 19.7)	10.2 (6.4 to 14.2)	7.8 (5.1 to 11.0)
Cystatin C equation	14.1 (12.2 to 16.2)	21.4 (18.2 to 24.9)	12.7 (8.5 to 17.4)	2.2 (0.6 to 3.9)
Creatinine–cystatin C equation	8.5 (7.0 to 10.2)	13.3 (10.7 to 16.1)	5.3 (2.7 to 8.2)	2.3 (0.9 to 4.2)
Average of creatinine and cystatin C equations†	8.2 (6.7 to 9.9)	12.1 (9.5 to 14.8)	6.4 (3.6 to 9.7)	2.9 (1.3 to 4.9)
1–P ₂₀				
Creatinine equation	32.9 (30.1 to 35.7)	37.2 (33.1 to 41.2)	31.1 (25.1 to 37.4)	26.5 (21.7 to 31.4)
Cystatin C equation	33.0 (30.3 to 35.7)	42.1 (38.2 to 46.1)	29.3 (23.6 to 35.4)	19.4 (15.4 to 23.7)
Creatinine–cystatin C equation	22.8 (20.4 to 25.2)	28.6 (25.1 to 32.4)	17.8 (13.3 to 22.9)	16.2 (12.4 to 20.5)
Average of creatinine and cystatin C equations†	23.7 (21.3 to 26.1)	29.1 (25.7 to 32.8)	17.6 (13.2 to 22.4)	18.8 (14.6 to 23.2)

ORIGINAL ARTICLE

Cystatin C–Based Equation to Estimate GFR without the Inclusion of Race and Sex

H. Pottel, J. Björk, A.D. Rule, N. Ebert, B.O. Eriksen, L. Dubourg, E. Vidal-Petiot, A. Grubb, M. Hansson, E.J. Lamb, K. Littmann, C. Mariat, T. Melsom, E. Schaeffner, P.-O. Sundin, A. Åkesson, A. Larsson, E. Cavalier, J.B. Bukabau, E.K. Sumaili, E. Yayo, D. Monnet, M. Flamant, U. Nyman, and P. Delanaye


ABSTRACT

N Engl J Med 2023;388:333-43.

First step: cystatin C and age

Laboratory data from
Sweden
N=227,643
♀ 95,469
♂ 132,174

Figure S3. Cystatin C versus age and the median quantile line for the 227,643 included subjects.




$$\begin{aligned} \text{♀ } Q' &= 0.79 \text{ mg/L until 50 y,} \\ &Q' = 0.79 + 0.005 \times (\text{Age} - 50) \\ \text{♂ } Q' &= 0.86 \text{ mg/L until 50 y} \\ &Q' = 0.86 + 0.005 \times (\text{Age} - 50) \end{aligned}$$

First step: cystatin C and **sex**

Laboratory data from
Sweden
N=227,643
♀ 95,469
♂ 132,174


Figure S3. Cystatin C versus age and the median quantile line for the 227,643 included subjects.



$$\begin{aligned} \text{♀ } Q' &= 0.79 \text{ mg/L until 50 y,} \\ & Q' = 0.79 + 0.005 \times (\text{Age} - 50) \\ \text{♂ } Q' &= 0.86 \text{ mg/L until 50 y} \\ & Q' = 0.86 + 0.005 \times (\text{Age} - 50) \end{aligned}$$

Second step: cystatin C and sex

Figure S4. Median plasma cystatin C in one-year intervals against age for men and women. A mathematical model to define Q'-values is proposed (red solid line): for adults Q' = 0.79 mg/L (women, dashed line) and 0.86 mg/L (men, solid line) until 50 years and a linear increasing model thereafter.



$$Q' = 0.83 \text{ mg/L until 50 years}$$
$$Q' = 0.83 + 0.005 \times (\text{Age} - 50)$$

Third step: Cystatin C and race

- Data from the same center in France
- Same method for GFR (Cr-EDTA), creatinine and cystatin C measurements
- Black and White people

Table S3. Patient characteristics of the entire cohorts used for the matching analysis (mean \pm SD)

Ethnicity/Sex	N	Age (years)	BMI (kg/m ²)	mGFR (mL/min/1.73m ²)	SCr (mg/dL)	CysC (mg/L)
White Men	1296 (57%)	53.0 \pm 14.6	26.2 \pm 4.9	61.8 \pm 26.0	1.52 \pm 0.73	1.52 \pm 0.68
Black Men	436 (63%)	50.7 \pm 13.1	26.3 \pm 4.5	62.0 \pm 22.1	1.73 \pm 0.81	1.41 \pm 0.61
White Women	966 (43%)	52.5 \pm 15.2	25.8 \pm 6.2	62.8 \pm 26.8	1.16 \pm 0.61	1.38 \pm 0.73
Black Women	261 (37%)	51.9 \pm 15.2	27.4 \pm 5.8	59.1 \pm 25.6	1.40 \pm 0.79	1.46 \pm 0.76

Third step: Cystatin C and race

Matched analysis 1:1 for

- sex
- BMI (± 2.5 kg/m²)
- Measured GFR (± 3 mL/min/1.73m²)
- age (± 3 y)

Table S4. Demographic and renal characteristics of the matched White and Black subjects (mean \pm SD)

Sex	N	Age (years)	BMI (kg/m ²)	mGFR (mL/min/1.73m ²)	SCr (mg/dL)	CysC (mg/L)
White Men	377	51.1 \pm 12.2	25.7 \pm 3.4	63.8 \pm 21.0	1.43 \pm 0.62	1.41 \pm 0.56
Black Men	377	50.8 \pm 12.3	25.8 \pm 3.5	63.6 \pm 21.0	1.65 \pm 0.64	1.37 \pm 0.59
White Women	200	53.4 \pm 11.9	26.1 \pm 4.6	59.7 \pm 23.2	1.16 \pm 0.53	1.40 \pm 0.69
Black Women	200	53.3 \pm 11.9	26.2 \pm 4.6	59.8 \pm 23.1	1.33 \pm 0.61	1.41 \pm 0.64

Fourth Step: Validation of the new equation

$$\text{EKFC} - \text{eGFR} = 107.3/[\text{Biomarker}/\text{Q}]^\alpha \times \\ [0.990^{(\text{Age}-40)} \text{ if age } >40 \text{ years}],$$

with $\alpha=0.322$ when biomarker/Q is less than 1
and $\alpha=1.132$ when biomarker/Q is 1 or more.

Adults

Measured GFR, IDMS traceable creatinine, calibrated cystatin C
N=12,832

11 cohorts

White Europeans: n=7,727

White Europeans from Paris: n=2,646

White US: n=1,093

Black Europeans from Paris: n=858

Black Africans: n=508

Table 1. Performance of Single Biomarker (Serum Creatinine or Cystatin C)–Based Equations to Estimate the Glomerular Filtration Rate.*

Variable	Serum Creatinine–Based Equations		
	CKD-EPI eGFR _{cr} (ASR)	CKD-EPI eGFR _{cr} (AS)	EKFC eGFR _{cr}
EKFC cohort, 7727 White patients			
Median bias (95% CI) — ml/min/1.73 m ² †	3.96 (3.67 to 4.32)	7.40 (7.02 to 7.76)	0.58 (0.32 to 0.86)
IQR of estimated GFR– measured GFR— ml/min/1.73 m ² ‡	15.5 (–3.0 to 12.5)	16.3 (0.0 to 16.3)	14.5 (–6.5 to 8.0)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	14.8 (14.4 to 15.2)	16.3 (15.9 to 16.6)	13.1 (12.8 to 13.4)
P ₃₀ — % (95% CI)¶	40.3 (39.2 to 41.4)	34.7 (33.6 to 35.8)	43.3 (42.2 to 44.4)
P ₉₀ — % (95% CI)‖	81.6 (80.8 to 82.5)	75.7 (74.8 to 76.7)	85.8 (85.0 to 86.5)

7.40 (7.02 to 7.76)	0.58 (0.32 to 0.86)
16.3 (0.0 to 16.3)	14.5 (–6.5 to 8.0)
16.3 (15.9 to 16.6)	13.1 (12.8 to 13.4)
34.7 (33.6 to 35.8)	43.3 (42.2 to 44.4)
75.7 (74.8 to 76.7)	85.8 (85.0 to 86.5)

Table 1. Performance of Single Biomarker (Serum Creatinine or Cystatin C)-Based Equations to Estimate the Glomerular Filtration Rate.*

Variable	Cystatin C-Based Equations	
	CKD-EPI eGFR _{cys}	EKFC eGFR _{cys} without Sex
EKFC cohort, 7727 White patients		
Median bias (95% CI) — ml/min/1.73 m ² †	0.28 (-0.02 to 0.64)	0.00 (-0.37 to 0.27)
IQR of estimated GFR- measured GFR— ml/min/1.73 m ² ‡	19.1 (-7.9 to 11.2)	14.4 (-7.9 to 6.5)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	15.8 (15.5 to 16.1)	13.5 (12.9 to 14.1)
P ₃₀ — % (95% CI)¶	32.0 (31.0 to 33.0)	41.7 (40.6 to 42.8)
P ₃₀ — % (95% CI)‖	80.8 (79.9 to 81.7)	86.2 (85.4 to 87.0)

Cystatin C-Based Equations

CKD-EPI eGFR _{cys}	EKFC eGFR _{cys} without Sex
0.28 (-0.02 to 0.64)	0.00 (-0.37 to 0.27)
19.1 (-7.9 to 11.2)	14.4 (-7.9 to 6.5)
15.8 (15.5 to 16.1)	13.5 (12.9 to 14.1)
32.0 (31.0 to 33.0)	41.7 (40.6 to 42.8)
80.8 (79.9 to 81.7)	86.2 (85.4 to 87.0)

Table 1. Performance of Single Biomarker (Serum Creatinine or Cystatin C)–Based Equations to Estimate the Glomerular Filtration Rate.*

Variable	Serum Creatinine–Based Equations			Cystatin C–Based Equations	
	CKD-EPI eGFR _{cr} (ASR)	CKD-EPI eGFR _{cr} (AS)	EKFC eGFR _{cr}	CKD-EPI eGFR _{cys}	EKFC eGFR _{cys} without Sex
EKFC cohort, 7727 White patients					
Median bias (95% CI) — ml/min/1.73 m ² †	3.96 (3.67 to 4.32)	7.40 (7.02 to 7.76)	0.58 (0.32 to 0.86)	0.28 (–0.02 to 0.64)	0.00 (–0.37 to 0.27)
IQR of estimated GFR– measured GFR— ml/min/1.73 m ² ‡	15.5 (–3.0 to 12.5)	16.3 (0.0 to 16.3)	14.5 (–6.5 to 8.0)	19.1 (–7.9 to 11.2)	14.4 (–7.9 to 6.5)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	14.8 (14.4 to 15.2)	16.3 (15.9 to 16.6)	13.1 (12.8 to 13.4)	15.8 (15.5 to 16.1)	13.5 (12.9 to 14.1)
P ₃₀ — % (95% CI)¶	40.3 (39.2 to 41.4)	34.7 (33.6 to 35.8)	43.3 (42.2 to 44.4)	32.0 (31.0 to 33.0)	41.7 (40.6 to 42.8)
P ₉₀ — % (95% CI)‖	81.6 (80.8 to 82.5)	75.7 (74.8 to 76.7)	85.8 (85.0 to 86.5)	80.8 (79.9 to 81.7)	86.2 (85.4 to 87.0)

Table 2. Performance of Combined Serum Creatinine– and Cystatin C–Based Equations to Estimate GFR.*

Variable	CKD-EPI eGFRcr-cys(ASR)	CKD-EPI eGFRcr-cys(AS)	EKFC eGFRcr-cys without Sex
EKFC cohort, 7727 White patients			
Median bias (95% CI) — ml/min/1.73 m ² †	2.50 (2.17 to 2.76)	5.04 (4.69 to 5.36)	0.37 (0.14 to 0.66)
IQR of estimated GFR – measured GFR — ml/min/1.73 m ² ‡	14.8 (–3.6 to 11.2)	16.7 (–1.8 to 14.9)	12.0 (–5.9 to 6.1)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	13.1 (12.8 to 13.4)	14.7 (14.4 to 15.0)	11.3 (11.0 to 11.6)
P ₁₀ — % (95% CI) ¶	41.5 (40.4 to 42.6)	37.2 (36.2 to 38.3)	48.9 (47.8 to 50.0)
P ₃₀ — % (95% CI)	88.3 (87.6 to 89.0)	84.2 (83.4 to 85.0)	90.4 (89.8 to 91.1)
Paris cohort, 2646 White patients			
Median bias (95% CI) — ml/min/1.73 m ² †	–1.35 (–1.82 to –0.97)	0.64 (0.16 to 1.15)	–0.65 (–1.06 to –0.23)
IQR of estimated GFR – measured GFR — ml/min/1.73 m ² ‡	13.4 (–7.5 to 5.8)	14.1 (–5.8 to 8.3)	12.4 (–6.8 to 5.6)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	12.1 (11.6 to 12.7)	12.6 (12.0 to 13.1)	11.8 (11.2 to 12.4)
P ₁₀ — % (95% CI) ¶	43.9 (42.0 to 45.8)	42.3 (40.4 to 44.1)	45.8 (43.9 to 47.7)
P ₃₀ — % (95% CI)	89.7 (88.5 to 90.8)	89.2 (88.0 to 90.4)	92.1 (91.1 to 93.1)
U.S. cohort, 1093 White patients			
Median bias (95% CI) — ml/min/1.73 m ² †	9.23 (8.45 to 10.10)	13.9 (13.1 to 14.9)	0.97 (0.01 to 2.12)
IQR of estimated GFR – measured GFR — ml/min/1.73 m ² ‡	18.4 (0.5 to 18.8)	18.1 (5.1 to 23.3)	17.4 (–8.2 to 9.2)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	18.1 (17.1 to 19.1)	21.0 (20.1 to 22.0)	15.5 (14.3 to 16.7)
P ₁₀ — % (95% CI) ¶	37.1 (34.3 to 40.0)	28.1 (25.4 to 30.8)	45.7 (42.7 to 48.6)
P ₃₀ — % (95% CI)	79.5 (77.1 to 81.9)	72.1 (69.4 to 74.8)	88.7 (86.9 to 90.6)
Paris cohort, 858 Black patients			
Median bias (95% CI) — ml/min/1.73 m ² †	–0.37 (–1.06 to 0.57)	–2.08 (–2.71 to –1.32)	–0.65 (–1.23 to 0.11)
IQR of estimated GFR – measured GFR — ml/min/1.73 m ² ‡	15.2 (–6.4 to 8.8)	14.0 (–7.9 to 6.1)	12.4 (–6.2 to 6.2)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	13.3 (11.9 to 14.6)	12.6 (11.2 to 13.9)	11.6 (10.0 to 13.0)
P ₁₀ — % (95% CI) ¶	38.7 (35.4 to 42.0)	38.9 (35.7 to 42.2)	48.3 (44.9 to 51.6)
P ₃₀ — % (95% CI)	87.9 (85.7 to 90.1)	89.0 (87.0 to 91.1)	92.0 (90.1 to 93.8)
African cohort, 508 Black patients			
Median bias (95% CI) — ml/min/1.73 m ² †	8.55 (6.87 to 10.30)	4.08 (2.37 to 5.78)	0.42 (–1.03 to 1.51)
IQR of estimated GFR – measured GFR — ml/min/1.73 m ² ‡	24.7 (–4.5 to 20.1)	22.0 (–7.4 to 14.7)	17.1 (–7.2 to 10.0)
Root-mean-square error (95% CI) — ml/min/1.73 m ² §	19.7 (18.2 to 21.1)	17.2 (15.8 to 18.5)	14.7 (13.3 to 16.0)
P ₁₀ — % (95% CI) ¶	28.7 (24.8 to 32.7)	34.3 (30.1 to 38.4)	43.5 (39.2 to 47.8)
P ₃₀ — % (95% CI)	75.0 (71.2 to 78.8)	77.6 (73.9 to 81.2)	84.3 (81.1 to 87.4)

Accuracy of GFR estimating equations based on creatinine, cystatin C or both in routine care

Edouard L. Fu^{1,2,3}, Andrew S. Levey⁴, Josef Coresh⁵, Morgan E. Grams⁶, Anne-Laure Faucon^{10,7}, Carl-Gustaf Elinder⁸, Friedo W. Dekker³, Pierre Delanaye^{9,10}, Lesley A. Inker⁴ and Juan-Jesus Carrero^{10,11}

¹Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

²Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

³Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

⁴Division of Nephrology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA

⁵Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

⁶Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA

⁷INSERM UMR 1018, Department of Clinical Epidemiology, Paris-Saclay University, Paris, France

⁸Division of Renal Medicine, Department of Clinical Intervention, and Technology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

⁹Department of Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium

¹⁰Department of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carêmeau, Nîmes, France

¹¹Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden

Correspondence to: Edouard L. Fu; E-mail: edfu@wh.harvard.edu



Accuracy of GFR-estimating equations based on creatinine, cystatin C or both in routine care

The focus of the study was the performance of eGFR equations in routine practice, including new CKD-EPI (2021) and EKFC (2021, 2023) equations.

Methods



6174 adults referred for single-point plasma clearance of iohexol, 9579 observations



Creatinine and cystatin C



SCREAM, Stockholm, Sweden
Routine referrals 2011–2021

Results

Bias*
(mL/min/1.73 m²)

eGFR_{cr}

0.2 to +9.1



eGFR_{cr-cys}

-1.5 to +2.5



P30* (%)

68 – 82



88 – 91



*Across varied equations:

CKD-EPI = CKD Epidemiology Collaboration; EKFC = European Kidney Function Consortium;
CAPA = Caucasian, Asian, Pediatric and Adult; RLM = revised Lund-Malmö.

Table 2: Bias, IQR, P₃₀ and correct classification of different GFR estimating equations compared with single-point plasma iohexol clearance.

	Bias, mL/min/ 1.73 m ² (95% CI) ^a	IQR, mL/min/1.73 m ² (Q1, Q3) ^b	P ₃₀ , % (95% CI) ^c	Correct classification, % (95% CI) ^d
Creatinine-based equations				
CKD-EPI 2009	5.6 (5.3 to 6.0)	17.6 (-2.3 to 15.3)	74.1 (73.2 to 75.0)	56.4 (55.4 to 57.4)
CKD-EPI 2021	9.1 (8.8 to 9.5)	18.6 (0.6 to 19.2)	68.1 (67.2 to 69.1)	51.8 (50.9 to 52.8)
EKFC 2021	2.7 (2.5 to 3.0)	15.6 (-4.6 to 11.0)	79.5 (78.7 to 80.3)	58.9 (57.9 to 59.9)
RLM 2011	0.2 (-0.2 to 0.4)	15.6 (-7.7 to 7.9)	82.2 (81.4 to 82.9)	58.6 (57.6 to 59.5)
Cystatin C-based equations				
CKD-EPI 2012	-2.6 (-2.9 to -2.3)	15.0 (-10.4 to 4.6)	82.5 (81.7 to 83.3)	58.3 (57.4 to 59.3)
EKFC 2023	-1.1 (-1.4 to -0.9)	14.6 (-11.5 to 3.1)	84.5 (83.8 to 85.2)	60.8 (59.8 to 61.7)
CAPA 2014	-3.7 (-4.0 to -3.4)	14.8 (-9.0 to 5.8)	83.2 (82.5 to 84.0)	58.1 (57.2 to 59.1)
Creatinine-cystatin C-based equations				
CKD-EPI 2012	0.8 (0.6 to 1.0)	12.6 (-5.0 to 7.6)	89.1 (88.4 to 89.7)	66.7 (65.7 to 67.6)
CKD-EPI 2021	2.5 (2.3 to 2.8)	13.1 (-3.3 to 9.8)	87.6 (86.9 to 88.2)	66.3 (65.3 to 67.2)
Mean of EKFC eGFR _{cr} and EKFC eGFR _{cys}	1.0 (0.8 to 1.3)	12.0 (-7.9 to 4.1)	88.5 (87.9 to 89.2)	66.8 (65.8 to 67.7)
Mean of RLM and CAPA	-1.5 (-1.7 to -1.3)	12.0 (-5.2 to 6.8)	90.8 (90.2 to 91.4)	65.8 (64.8 to 66.7)

^aBias was expressed as the median difference in eGFR minus mGFR (95% CI). A negative bias indicates underestimation of the mGFR, and a positive bias indicates overestimation of the mGFR.

^bIQR is defined as the IQR and a measure of precision (the dispersion of individual errors around the bias).

^cP₃₀ was defined as the percentage of individuals with eGFRs within 30% of mGFR (95% CI).

^dCorrect classification of GFR categories was defined as agreement of eGFR and mGFR categories using the KDIGO GFR categories (<15, 15–29, 30–44, 45–59, 60–89 and ≥90 mL/min/1.73 m²).

	Overall
Iohexol measurements, n (%)	9579
Mean age (SD), years	56 (17)
Age ≥65 years, n (%)	3581 (37)
Female sex, n (%)	3826 (40)
Mean BMI (SD), kg/m ²	26 (8)

Cystatin C/EKFC

- Cystatin C allows an eGFR without race nor sex
- EKFC is mathematically the same as EKFC creatinine, only Q is changing
- Continuum between children and adults for EKFC_{crea}
- Equations based on cystatin C are not better than equations based on creatinine
- EKFC equations are slightly better than corresponding CKD-EPI equations => **good alternative to CKD-Epi in Europe and Africa**
- Combined equations are better (P30 +5-10%)
- Standardisation
- More costly
- How to manage discrepant results?
- Place of EKFC and/or cystatin C in the 2024 KDIGO?

<https://ekfccalculator.pages.dev/>



**KDIGO 2024 CLINICAL PRACTICE GUIDELINE
FOR THE EVALUATION AND MANAGEMENT
OF CHRONIC KIDNEY DISEASE**

1.2.4 Selection of GFR estimating equations

Recommendation 1.2.4.1: We recommend using a validated GFR estimating equation to derive GFR from serum filtration markers (eGFR) rather than relying on the serum filtration markers alone (1D).

Practice Point 1.2.4.1: Use the same equation within geographical regions (as defined locally [e.g., continent, country, and region] and as large as possible). Within such regions, equations may differ for adults and children.

Practice Point 1.2.4.2: Use of race in the computation of eGFR should be avoided.

Special considerations

Pediatric considerations

Practice Point 1.2.4.3: Estimate GFR in children using validated equations that have been developed or validated in comparable populations.

Table 14 | Validated GFR estimating equations

Marker	Equation name and year	Age	Variables	Development populations
Creatinine	CKD-EPI 2009 ²³⁸	≥18; modification CKD-EPI 40 for pediatric available	Developed using A, S, R but reported not using the Black race coefficient, A, S, R (NB)	8254 Black and NB individuals from 10 studies in the United States and Europe ^a
	CKiD U25 2021 ²³⁹	1–25	A, S, height	928 children with CKD in the United States and Canada
	CKD-EPI 2021 ¹⁴⁷	≥18	A, S	8254 Black and NB individuals from 10 studies in the United States and Europe ^a
	EKFC 2021 ²⁴⁰	2–100	A, S, European Black and NB specific Q-value; separate Q-values for Africa vs. Europe	mGFR vs. SCr (11,251 participants in 7 studies in Europe and 1 study from the United States) Normal GFR from 5482 participants in 12 studies of kidney donor candidates (100% Caucasian) European NB Q from 83,157 laboratory samples (age 2–40 years) in 3 European hospital clinical laboratories; European Black Q-value (N = 90 living kidney donors from Paris); African Black Q-value (N = 470 healthy individuals from République Démocratique de Congo); All Q-values developed in cohorts independent for EKFC development and validation
Cystatin C	CKD-EPI 2012 ¹⁴⁸	≥18	A, S	5352 Black and NB individuals from 13 studies in the United States and Europe
	EKFC 2023 ⁹¹	18–100	A	mGFR vs. SCys (assumed to be the same as mGFR vs. SCr) Normal GFR (same as for the SCr equation) Q from laboratory samples from 227,643 (42% female) laboratory samples from Uppsala University Hospital, Sweden

Limitations of equations = creatinine

Specific populations:
Equations are not magic!
Keep our clinical feeling!!

Anorexia Nervosa (Delanaye P, Clin Nephrol, 2009, 71, 482)

Cirrhosis (Skruzacek PA, Am J Kidney Dis, 2003, 42, 1169)

ICU (Delanaye P, BMC Nephrology, 2014, 15, 9)

Hospitalized (Poggio ED, Am J Kidney Dis, 2005, 46, 242)

Heart Transplanted (Delanaye P, Clin Transplant, 2006, 20, 596)

Kidney Transplanted (Masson I, Transplantation, 2013, 95, 1211)

Obesity (Bouquegneau A, NDT, 2013, 28, iv122)

Do not over-interpret an eGFR result...

All equations remain estimation...

Good at the population level

Lack of precision at the individual level




Fig. 1. Uncertainty of eGFR calculated using the CKD-EPI equations for African-Americans and non-African-Americans at various creatinine concentrations for a 50-year-old male. Circles (red, larger values) indicate African-American and diamonds (green, lower values) indicate non-African-American equations. Plot symbols are the eGFR values and error bars represent the 95% CI for each eGFR value.

$$eGFR = 60,25 \text{ ml/min/1.73m}^2$$




Fig. 1. Uncertainty of eGFR calculated using the CKD-EPI equations for African-Americans and non-African-Americans at various creatinine concentrations for a 50-year-old male. Circles (red, larger values) indicate African-American and diamonds (green, lower values) indicate non-African-American equations. Plot symbols are the eGFR values and error bars represent the 95% CI for each eGFR value.

$$\begin{aligned}
 \text{eGFR} &= \cancel{60,25 \text{ ml/min/1.73m}^2} \\
 &= 60 \text{ ml/min/1.73m}^2 \quad (\text{CI } 95\%: 33-87)
 \end{aligned}$$

The applicability of eGFR equations to different populations

Pierre Delanaye and Christophe Mariat



GO BACK to MEASURED GFR

Delanaye P, Nature Rev Nephrol, 2013, 9, p513

Ebert N, Clin Kidney J, 2021, 14, p1861

Agarwal R, Nephrol Dial Transplant, 2019, 34, p2001

Shafi T, Ann Intern Med, 2022, 175, p1073

Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium



OPEN

Natalie Ebert^{1,25}, Elke Schaeffner^{1,25}, Jesse C. Seegmiller², Marco van Londen³, Arend Bökenkamp⁴, Etienne Cavalier⁵, Pierre Delanaye^{6,7}, Laurence Derain-Dubourg⁸, Bjørn O. Eriksen⁹, Olafur S. Indridason¹⁰, Runolfur Palsson^{10,11}, Tariq Shafi¹², Anders Christensson¹³, Sebastjan Bevc^{14,15}, Fabiola Carrara¹⁶, Marie Courbebaisse¹⁷, R. Neil Dalton¹⁸, Markus van der Giet¹⁹, Toralf Melsom⁹, Shona Methven²⁰, Gunnar Nordin²¹, Hans Pottel²², Andrew D. Rule²³, Matias Trillini¹⁶ and Christine A. White²⁴; and the European Federation of Clinical Chemistry and Laboratory Medicine Task Group on Chronic Kidney Disease (EFLM TG-CKD)

¹Charité Universitätsmedizin Berlin, Institute of Public Health, Berlin, Germany; ²Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA; ³Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands; ⁴Department of Pediatric Nephrology, Amsterdam University Medical Centers, Amsterdam, the Netherlands; ⁵Department of Clinical Chemistry, University of Liège, Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium; ⁶Department of Nephrology-Dialysis-Transplantation, University of Liège, Centre Hospitalier Universitaire du Sart-Tilman, Liège (ULiege), Belgium; ⁷Department of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carémeau, Nîmes, France; ⁸Service de Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France; ⁹Section of Nephrology, University Hospital of North Norway and Metabolic and Renal Research Group, UiT, The Arctic University of Norway, Tromsø, Norway; ¹⁰Division of Nephrology, Landspítali University Hospital, Reykjavik, Iceland; ¹¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ¹²Division of Kidney Diseases, Hypertension and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA; ¹³Department of Nephrology, Skåne University Hospital, Lund University, Malmö, Sweden; ¹⁴Department of Nephrology, Department of Pharmacology, University Medical Centre Maribor, Maribor, Slovenia; ¹⁵Faculty of Medicine, University of Maribor, Maribor, Slovenia; ¹⁶Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy; ¹⁷Université Paris Cité; Physiology Department, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France; ¹⁸The WellChild Laboratory, Evelina London Children's Hospital, London, UK; ¹⁹Department of Nephrology, Charité-Universitätsmedizin Berlin, Berlin, Germany; ²⁰Department of Renal Medicine, Aberdeen Royal Infirmary, Scotland, UK; ²¹Equalis AB, Uppsala, Sweden; ²²Department of Public Health and Primary Care, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Kortrijk, Belgium; ²³Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; and ²⁴Department of Medicine, Queen's University, Kingston, Ontario, Canada

Kidney International (2024) **106**, 583–596;

Iohexol plasma clearance

Not so cumbersome

Not so costly

- Reimbursed in Belgium
- Kidney Day concept
- Available in every (university?) hospital (?)

Table 3 | Multiple sample protocols




Expected patient's GFR based on eGFR	Initial and final blood sampling times after iohexol injection ^a
eGFR <30 ml/min per 1.73 m ²	At 4 and 10 h with additional 1–2 hourly samples in between ^b
eGFR 30–59 ml/min per 1.73 m ²	At 3 and 7 h with additional 1–1.5 hourly samples in between
eGFR >60 ml/min per 1.73 m ²	At 2 and 4 h with additional 0.5–1 hourly samples in between
Clinical signs of excessive volume overload: edema (grades 3–4: ≥6-mm pit lasting for >1 min after 5-s compression over tibia or medial malleolus ³³) or ascites	Use urinary clearance

eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.

^aAt least 4 samples are recommended to ensure that at least 3 values are usable for GFR and R^2 calculation if a single sample is unavailable or excluded.

^bIf 10-hour sampling is not logistically feasible, a final sample at 8 or 24 hours is recommended. All samples should be timed to the minute of collection after injection, and these times should be used in the GFR calculation.

GFR Measurement Using Transdermal Detection Methodology

Richard B. Dorshow , Martin P. Debreczeny , and Stuart L. Goldstein 

In January, the U.S. Food and Drug Administration approved the MediBeacon TGFR including Lumitrace injection for the assessment of kidney function in patients with normal or impaired renal function. In February, the NMPA approved the MediBeacon TGFR Monitor and MediBeacon TGFR Sensor in China where Lumitrace[®] (relmapirazin) injection is categorized as a drug with a separate approval process.




Figure 1. Components of the fluorescence detection system. (A) Sensor module containing the light-emitting diodes and photodetectors. (B) Sensor placement on the body. (C) Schematic of the system in use.

A difficult path to point-of-care measurement of glomerular filtration rate

Pierre Delanaye & Richard J. Glassock


“In settings such as kidney donor evaluations or oncology ... accuracy is more important than immediacy”

“External validations by independent research groups are anticipated and necessary”

European Kidney Function Consortium



© Jacques Leclerc 2019



Laurence Derain Dubourg, Lyon
François Gaillard, Lyon, Paris
Marie Courbebaisse, Paris
Lionel Couzi, Bordeaux
Cyril Garrouste, Clermont Ferrand
Lola Jacquemont, Nantes
Nassim Kamar, Toulouse
Christophe Legendre, Paris
Lionel Rostaing, Grenoble
Christophe Mariat, Saint-Etienne
Olivier Moranne, Nîmes
Thomas Stehlé, Créteil
Antoine Lanot, Caen



Arend Bökenkamp, Amsterdam
Stephan J.L. Bakker, Groningen
Martin H. de Borst, Groningen
Marco van Londen, Groningen



Toralf Melsom, Tromsø
Bjørn-Odvar Eriksen, Tromsø



Pierre Delanaye, Liège
Hans Pottel, Kortrijk
Etienne Cavalier, Liège



Jonas Björk, Lund
Ander Grubb, Lund
Magnus Hansson, Stockholm
Karin Littmann, Stockholm
Per-Ola Sundin, Örebro
Anna Åkesson, Lund
Anders Larsson, Uppsala
Ulf Nyman, Lund
Anders Christensson, Stockholm



Natalie Ebert, Berlin
Elke Schaeffner, Berlin



Justine Bukabau, Kinshasa
Ernest Sumaili, Kinshasa



Eric Yayo, Abidjan



Andrew Rule, Rochester

Thanks for your attention

